| 1. |
- Elgqvist, Jörgen, 1963, et al.
(författare)
-
Ovarian cancer: background and clinical perspectives
- 2010
-
Ingår i: Targeted Radionuclide Therapy. - Philadelphia, USA : Lippincott Williams &Wilkins, a Wolter Kluwer business. - 9780781796934 ; , s. 380-396
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 2. |
|
|
| 3. |
- Kjeller, Göran
(författare)
-
Management of Patients Undergoing Radiation and Chemotherapy
- 2010
-
Ingår i: Oral and Maxillofacial Surgery (Eds: Andersson L, Kahnberg K-E, Pogrel AM. - ChiChester, UK : Blackwell Publishing Ltd. - 9781405171199 ; , s. 735-742
-
Bokkapitel (refereegranskat)abstract
- This chapter describes the types of tumor and the criteria for treating them with radiation therapy alone, radiation therapy combined with surgery, radiation therapy combined with chemotherapy, and radiation therapy combined with both chemotherapy and surgery. The different protocols available for the different types of tumor will be described, including the different order in which they may be given. The side-effects of radiation therapy and chemotherapy are described as well as the long-term oral complications from both types of therapy.
|
|
| 4. |
- Pietras, Alexander, et al.
(författare)
-
The HIF-2alpha-Driven Pseudo-Hypoxic Phenotype in Tumor Aggressiveness, Differentiation, and Vascularization.
- 2010
-
Ingår i: Diverse Effects of Hypoxia on Tumor Progression. - Berlin, Heidelberg : Springer Berlin Heidelberg. - 0070-217X. - 9783642133299 - 9783642133282 ; 345, s. 1-20
-
Bokkapitel (refereegranskat)abstract
- Cellular adaptation to diminished tissue oxygen tensions, hypoxia, is largely governed by the hypoxia inducible transcription factors, HIF-1 and HIF-2. Tumor hypoxia and high HIF protein levels are frequently associated with aggressive disease. In recent years, high tumor cell levels of HIF-2 and the oxygen sensitive subunit HIF-2alpha have been associated with unfavorable disease and shown to be highly expressed in tumor stem/initiating cells originating from neuroblastoma and glioma, respectively. In these cells, HIF-2 is active under nonhypoxic conditions as well, creating a pseudo-hypoxic phenotype with clear influence on tumor behavior. Neuroblastoma tumor initiating cells are immature with a neural crest-like phenotype and downregulation of HIF-2alpha in these cells results in neuronal sympathetic differentiation and the cells become phenotypically similar to the bulk of neuroblastoma cells found in clinical specimens. Knockdown of HIF-2alpha in neuroblastoma and glioma tumor stem/initiating cells leads to reduced levels of VEGF and poorly vascularized, highly necrotic tumors. As high HIF-2alpha expression further correlates with disseminated disease as demonstrated in neuroblastoma, glioma, and breast carcinoma, we propose that targeting HIF-2alpha and/or the pseudo-hypoxic phenotype induced by HIF-2 under normoxic conditions has great clinical potential.
|
|
